Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 115 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacology, Clinical Clear all
Completed Phase 1 Interventional

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

NCT03313557
View directory record Official record
Conditions
Solid Tumors
Interventions
Wee-1 kinase inhibitor AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 4 Interventional

Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging

NCT00976053
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Myocardial perfusion imaging
Procedure
Lead sponsor
Aspire Foundation
Other
Eligibility
30 Years to 90 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 28, 2026, 11:13 PM EDT
Active, not recruiting Phase 1 Interventional Results available

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

NCT04900792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide
Drug · Radiation
Lead sponsor
Bryan Allen
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain

NCT00142519
View directory record Official record
Conditions
Pain
Interventions
Methadone, methadone and morphine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Individualized Obesity Pharmacotherapy

NCT03374956
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

NCT02852239
View directory record Official record
Conditions
Renal Impairment
Interventions
dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
DeBary, Florida • Berlin, New Jersey • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 28, 2026, 11:13 PM EDT
Terminated Phase 1 Interventional

Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

NCT04865159
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Tipifarnib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Canton, Ohio • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 4 Interventional

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05657860
View directory record Official record
Conditions
Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions
Guanfacine Extended Release, Placebo
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 28, 2026, 11:13 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Computerized Cognitive Training in Young Adults With Depression

NCT03869463
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Computerized Cognitive Training, Control
Other
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
18 Years to 29 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Characterizing Clinical and Pharmacological Neuroimaging Biomarkers

NCT03842800
View directory record Official record
Conditions
Cognitive Impairment
Interventions
MRI, Ketamine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 28, 2026, 11:13 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

NCT05999383
View directory record Official record
Conditions
THC, Cannabis, Cannabis Use, Cannabis Smoking, Tobacco Use, Vaping
Interventions
Cannabis, Nicotine, Pax Loose Leaf Vaporizer, Placebo Marijuana
Drug · Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pomaglumetad Effects on Glutamate Biomarkers

NCT02919774
View directory record Official record
Conditions
Healthy Controls
Interventions
POMA, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease

NCT00455546
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
A-002
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
23
States / cities
Mobile, Alabama • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 QT Study in Healthy Male Subjects

NCT01986894
View directory record Official record
Conditions
Clinical Pharmacology, Healthy Volunteer Study
Interventions
Placebo, Pomalidomide, Moxifloxacin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

NCT03962049
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
Linzagolix
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 28, 2026, 11:13 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation

NCT07058974
View directory record Official record
Conditions
Smokers, Former Smokers
Interventions
lamivudine, rapamycin, Exercise Regimen, Spermidine
Drug · Behavioral · Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Not yet recruiting Not applicable Interventional

Comparing Non-Medicine Strategies for Improving Low Back Pain

NCT07679178
View directory record Official record
Conditions
Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Interventions
ENCompaSS (Education, Navigated Care, and Supported Self-Management) with VA Stepped Usual Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects

NCT03517943
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Micronutrient Supplementation in Children With ASD

NCT05268744
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Micronutrient
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
5 Years to 22 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Irinotecan in Treating Aging Patients With Solid Tumors

NCT00026195
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
47
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.

NCT02394093
View directory record Official record
Conditions
Pharmacology, Clinical
Interventions
Aspirin (Acetylsalicylic acid, BAYe4465)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders

NCT03732248
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Dependence
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

NCT01692184
View directory record Official record
Conditions
Healthy
Interventions
50 mg AVL-292, 100 mg AVL-292, 200 mg AVL-292, 350 mg AVL-292, Placebo capsules
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Pyroxamide in Treating Patients With Advanced Cancer

NCT00042900
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyroxamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 28, 2026, 11:13 PM EDT